Loading
CAR-T Cell Therapy Research / Vaccines and Immunoinformatics Approaches · Journal article
Communications Biology · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This mechanistic study profiling three HER2/neu-specific TCR constructs using integrated multiomics reveals that Construct #3 demonstrates superior in vitro cytotoxicity and in vivo tumour regression despite identical antigen specificity, attributed to distinct transcriptional programs coupling cytolytic and cytokine secretion capacity. The work is exploratory, identifies a functional hierarchy and proposes molecular mechanisms via single-cell and bulk transcriptomics, but provides no comparative efficacy statistics, statistical testing, or clinical data.
Mechanistic exploratory study combining in vitro cytotoxicity assays, single-cell multiomics, bulk transcriptomics, cytokine profiling, and in vivo tumour modelling. Three HER2/neu-specific T cell receptor constructs; no human subjects or patient population described.. Intervention: Construct #3 HER2/neu-specific TCR. Compared with: Constructs #1 and #2 HER2/neu-specific TCRs.
Construct #3 displayed potent cytotoxicity in vitro and potent tumour regression in vivo, whereas Constructs #1 and #2 were less effective Single-cell proteotranscriptomic analysis shows tumour cell encounter drives activation of cytotoxic CD8+ T effector cells and transdifferentiation of NKT cells into APC-like cells In silico interactomics revealed high probability of communication between APC-like NKT cells and CD4+ T cells, potentially forming cooperative activation network
Construct #3 displayed potent cytotoxicity in vitro and potent tumour regression in vivo, whereas Constructs #1 and #2 were less effective
This work provides mechanistic insights into TCR functional heterogeneity and may inform rational design of superior TCR-based therapies. However, the lack of statistical comparison, effect sizes, and clinical translation limits immediate clinical guidance.
Single-centre mechanistic study of three TCR constructs using multimodal profiling with in vivo tumour modelling; identifies functional hierarchy but lacks comparative efficacy statistics, power calculation, or clinical translation.
As stated by the source record.
Quoted from the source exactly as published.
This work provides mechanistic insights into TCR functional heterogeneity and may inform rational design of superior TCR-based therapies. However, the lack of statistical comparison, effect sizes, and clinical translation limits immediate clinical guidance.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Adoptive T cell therapy targeting tumor-associated antigens offers a promising avenue for cancer immunotherapy, yet the mechanisms underlying functional heterogeneity among T cell receptors recognizing the same antigen remain poorly understood. Here, we comprehensively profile three HER2/neu-specific T cell receptor constructs using integrated multimodal analysis that combines in vitro cytotoxicity assays, single-cell multiomics, bulk transcriptomics, cytokine profiling, and in vivo tumor modeling. Despite identical antigen specificity, the constructs exhibit a functional hierarchy: Construct #3 displayed potent cytotoxicity in vitro and potent tumor regression in vivo, whereas Constructs #1 and #2 were less effective. Single-cell proteotranscriptomic analysis shows that tumor cell encounter drives activation of cytotoxic CD8⁺ T effector cells and transdifferentiation of NKT cells into APC-like cells. In silico interactomics also revealed a high probability of communication between APC-like NKT cells and CD4⁺ T cells, potentially forming a cooperative activation network that sustains effector function. Bulk transcriptomic and secretomic profiling showed that Construct #3 couples cytolytic gene expression with the secretion of anti-tumor cytokines and effector molecules. Together, these findings propose a mechanistic link between anti-HER2/neu T cell receptor-driven transcriptional programming and therapeutic efficacy, illustrating how multi-omic approaches can inform the rational design of potent T cell receptor-based therapies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.